Lobna Ibrahim

4.5k total citations · 2 hit papers
21 papers, 3.5k citations indexed

About

Lobna Ibrahim is a scholar working on Pharmacology, Biological Psychiatry and Psychiatry and Mental health. According to data from OpenAlex, Lobna Ibrahim has authored 21 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pharmacology, 11 papers in Biological Psychiatry and 9 papers in Psychiatry and Mental health. Recurrent topics in Lobna Ibrahim's work include Treatment of Major Depression (14 papers), Tryptophan and brain disorders (11 papers) and Bipolar Disorder and Treatment (9 papers). Lobna Ibrahim is often cited by papers focused on Treatment of Major Depression (14 papers), Tryptophan and brain disorders (11 papers) and Bipolar Disorder and Treatment (9 papers). Lobna Ibrahim collaborates with scholars based in United States, Brazil and Czechia. Lobna Ibrahim's co-authors include Carlos A. Zarate, Nancy Diazgranados, David A. Luckenbaugh, Nancy E. Brutsché, Rodrigo Machado‐Vieira, Ioline D. Henter, Giacomo Salvadore, Husseini K. Manji, Jose Franco‐Chaves and Craig A. Marquardt and has published in prestigious journals such as Biological Psychiatry, Neuropsychopharmacology and The Journal of Clinical Psychiatry.

In The Last Decade

Lobna Ibrahim

19 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression

2010 734 citations Nancy Diazgranados, Lobna Ibrahim et al. Archives of General Psychiatry profile →
Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial

2012 607 citations Carlos A. Zarate, Nancy E. Brutsché et al. Biological Psychiatry profile →

Peers

Countries citing papers authored by Lobna Ibrahim

Since Specialization

Citations

This map shows the geographic impact of Lobna Ibrahim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lobna Ibrahim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lobna Ibrahim more than expected).

Fields of papers citing papers by Lobna Ibrahim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lobna Ibrahim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lobna Ibrahim. The network helps show where Lobna Ibrahim may publish in the future.

Co-authorship network of co-authors of Lobna Ibrahim

This figure shows the co-authorship network connecting the top 25 collaborators of Lobna Ibrahim. A scholar is included among the top collaborators of Lobna Ibrahim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lobna Ibrahim. Lobna Ibrahim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unveiling the Therapeutic Potential of Targeting RRM2 in Hepatocellular Carcinoma: An Integrated In Silico and In Vitro Study 2025 ·Functional & Integrative Genomics ·Lobna Ibrahim, (unknown), Mahmoud M. Tolba, Sara M. Radwan, Nadia Μ. Hamdy, Mahmoud ElHefnawi	0
2	Earthquake Prediction using Hybrid Machine Learning Techniques 2021 ·International Journal of Advanced Computer Science and Applications ·Mustafa Abdul Salam, Lobna Ibrahim, Diaa Salama AbdElminaam	28
3	Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study 2013 ·Biological Psychiatry ·Paul J. Carlson, Nancy Diazgranados, Allison C. Nugent, Lobna Ibrahim, David A. Luckenbaugh, Nancy E. Brutsché, Peter Herscovitch, Husseini K. Manji, Carlos A. Zarate, Wayne C. Drevets	138
4	Neural correlates of rapid antidepressant response to ketamine in bipolar disorder 2013 ·Bipolar Disorders ·Allison C. Nugent, Nancy Diazgranados, Paul J. Carlson, Lobna Ibrahim, David A. Luckenbaugh, Nancy E. Brutsché, Peter Herscovitch, Wayne C. Drevets, Carlos A. Zarate	66
5	A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression 2012 ·Biological Psychiatry ·Carlos A. Zarate, Daniel C. Mathews, Lobna Ibrahim, (unknown), Craig A. Marquardt, (unknown), (unknown), Nancy E. Brutsché, Mark A. Smith, David A. Luckenbaugh	203
6	Replication of Ketamine's Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-On Trial breakdown → 2012 ·Biological Psychiatry ·Carlos A. Zarate, Nancy E. Brutsché, Lobna Ibrahim, Jose Franco‐Chaves, Nancy Diazgranados, Anibal Cravchik, Jessica Selter, Craig A. Marquardt, (unknown), David A. Luckenbaugh	607
7	Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study 2012 ·Neuropsychopharmacology ·Lobna Ibrahim, Nancy Diazgranados, Jose Franco‐Chaves, Nancy E. Brutsché, Ioline D. Henter, Phillip D. Kronstein, Ruin Moaddel, Irving W. Wainer, David A. Luckenbaugh, Husseini K. Manji, Carlos A. Zarate	242
8	A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder 2012 ·Journal of Clinical Psychopharmacology ·Lobna Ibrahim, Nancy Diazgranados, (unknown), Nancy E. Brutsché, David A. Luckenbaugh, W. Joseph Herring, William Z. Potter, Carlos A. Zarate	175
9	Family history of alcohol dependence and antidepressant response to an N‐methyl‐D‐aspartate antagonist in bipolar depression 2012 ·Bipolar Disorders ·David A. Luckenbaugh, Lobna Ibrahim, Nancy E. Brutsché, Jose Franco‐Chaves, Daniel C. Mathews, Craig A. Marquardt, Christy Cassarly, Carlos A. Zarate	54
10	Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment‐resistant bipolar depression 2012 ·British Journal of Clinical Pharmacology ·Xiaochen Zhao, Swarajya Lakshmi Vattem Venkata, Ruin Moaddel, Dave Luckenbaugh, Nancy E. Brutsché, Lobna Ibrahim, Carlos A. Zarate, Donald E. Mager, Irving W. Wainer	113
11	Novel glutamatergic agents for major depressive disorder and bipolar disorder 2011 ·Pharmacology Biochemistry and Behavior ·Rodrigo Machado‐Vieira, Lobna Ibrahim, Ioline D. Henter, Carlos A. Zarate	73
12	Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression 2011 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Lobna Ibrahim, Nancy Diazgranados, David A. Luckenbaugh, Rodrigo Machado‐Vieira, Jacqueline Baumann, Alan G. Mallinger, Carlos A. Zarate	147
13	Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study 2011 ·Brain Research Bulletin ·Lobna Ibrahim, W. Raymond Duncan, David A. Luckenbaugh, Peixiong Yuan, Rodrigo Machado‐Vieira, Carlos A. Zarate	37
14	An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression 2011 ·The International Journal of Neuropsychopharmacology ·Giacomo Salvadore, Jan Willem van der Veen, Yan Zhang, Stefano Marenco, Rodrigo Machado‐Vieira, Jacqueline Baumann, Lobna Ibrahim, David A. Luckenbaugh, Jun Shen, Wayne C. Drevets, Carlos A. Zarate	81
15	New Therapeutic Targets for Mood Disorders 2010 ·The Scientific World JOURNAL ·Rodrigo Machado‐Vieira, Giacomo Salvadore, Nancy Diazgranados, Lobna Ibrahim, David R. Latov, (unknown), Jacqueline Baumann, Ioline D. Henter, Carlos A. Zarate	50
16	Histone Deacetylases and Mood Disorders: Epigenetic Programming in Gene‐Environment Interactions 2010 ·CNS Neuroscience & Therapeutics ·Rodrigo Machado‐Vieira, Lobna Ibrahim, Carlos A. Zarate	93
17	A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression breakdown → 2010 ·Archives of General Psychiatry ·Nancy Diazgranados, Lobna Ibrahim, Nancy E. Brutsché, Andrew B. Newberg, Phillip D. Kronstein, (unknown), William Kammerer, Zenaide Quezado, David A. Luckenbaugh, Giacomo Salvadore, Rodrigo Machado‐Vieira, Husseini K. Manji, Carlos A. Zarate	734
18	Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder 2010 ·The Journal of Clinical Psychiatry ·Nancy Diazgranados, Lobna Ibrahim, Nancy E. Brutsché, Rezvan Ameli, Ioline D. Henter, David A. Luckenbaugh, Rodrigo Machado‐Vieira, Carlos A. Zarate	454
19	Glutamatergic Modulators: The Future of Treating Mood Disorders? 2010 ·Harvard Review of Psychiatry ·Carlos A. Zarate, Rodrigo Machado‐Vieira, Ioline D. Henter, Lobna Ibrahim, Nancy Diazgranados, Giacomo Salvadore	164
20	Targeting Glutamatergic Signaling for the Development of Novel Therapeutics for Mood Disorders 2009 ·Current Pharmaceutical Design ·Rodrigo Machado‐Vieira, Giacomo Salvadore, Lobna Ibrahim, Nancy Diazgranados, Carlos A. Zarate	80

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact